Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
116
resultados
Última actualización
03/08/2025 [06:49:00]
Resumen de: US2025241854A1
Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.
Resumen de: AU2025205348A1
Abstract The present disclosure relates to a copolymer and a polymersome for targeted delivery of biomolecules to a living organism. Hie exemplary copolymer comprises an initiator block, a propagator block, and a linkage connecting the initiator block and the propagator block. The initiator block comprises a glycan head configured to provide a targeted delivery, and the propagator block comprises a functional moiety configured to provide desired properties for the polymersome. Abstract The present disclosure relates to a copolymer and a polymersome for targeted delivery of biomolecules to a living organism. Hie exemplary copolymer comprises an initiator block, a propagator block, and a linkage connecting the initiator block and the propagator block. The initiator block comprises a glycan head configured to provide a targeted delivery, and the propagator block comprises a functional moiety configured to provide desired properties for the polymersome.
Resumen de: AU2023394992A1
The present invention relates to a messenger RNA (mRNA)-based immunogenic composition that is capable of inducing a mammalian cell to produce an influenza virus-like particle (VLP). The immunogenic composition comprises one or more mRNAs encoding an influenza virus matrix 1 (M1) protein and one or more influenza virus hemagglutinin (HA) proteins and/or one or more influenza virus neuraminidase (NA) proteins.
Resumen de: AU2024209247A1
41 P6105182WOThe invention relates to formulations comprising miRNA that have improved stability for the treatment of diseases including neurodegenerative diseases such as spinocerebellar ataxias type 3. 5
Resumen de: AU2024206838A1
The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject that, optionally, have reduced reactogenicity and promotes a local innate immune response in the subject while promoting an adaptive immune response. Compositions described herein include nanoparticles, optionally including an inorganic particle, capable of admixing with nucleic acids encoding proteins, antibodies, or immunomodulators. Methods of using the compositions as a therapeutic vaccine for the treatment of an infection or cancer are also provided.
Resumen de: AU2024223881A1
The present invention relates to methods for the purification of lipid nanoparticles (LNPs) encapsulating a nucleic acid, comprising the steps of subjecting a solution containing said LNPs to a chromatographic medium with convective flow properties in the presence of at least one kosmotropic agent; and eluting LNPs from said chromatographic medium. The present invention further relates to respective uses of a chromatographic medium with convective flow properties for the purification of lipid nanoparticles (LNPs) encapsulating a nucleic acid.
Resumen de: US2025243151A1
An ionizable lipid having a structure represented by the following formula (I):wherein Y is independently selected from a group consisting of —NH—, —O—, —S—, and a single bond; X is independently selected from —NR1R2 or a nitrogen-containing heteroaryl group; L1 and L2 are each independently selected from a group consisting of a C1-C10 alkylene group, a C2-C10 alkenylene group,R1 and R2 are each independently selected from a group consisting of H, a substituted or unsubstituted C1-C10 hydrocarbyl group, a substituted or unsubstituted C1-C10 heterohydrocarbyl group, a substituted or unsubstituted C6-C20 aryl group, and a substituted or unsubstituted C1-C20 heteroaryl group; R3 is a C5-C30 alkyl group; R4 is a C5-C30 alkyl group; n is an integer selected from 1 to 10; and m and p are each independently an integer selected from 1 to 20.
Resumen de: US2025241864A1
Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such a nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.
Resumen de: US2025241999A1
Systems for enhanced delivery of functional, recombinant soluble uricase enzymes with long serum residence, low immunogenicity and potential for modification have been developed. Compositions and methods of use thereof of nanoparticles including recombinant soluble uricase enzymes are provided for oral administration to a subject. The nanoparticle compositions include recombinant soluble uricase enzymes that are not PEGylated, and have a serum residence time of hours, days or weeks following oral administration. A reduced level of side effects of the formulation provides an effective and safe drug delivery platform for treating Tumor Lysis syndrome and Lesch-Nyhan disease, as well as hyperuricemia and associated diseases or disorders.
Resumen de: US2025241985A1
Disclosed herein are compositions comprising nanoliposomes useful for the treatment and prevention of stroke.
Resumen de: AU2023347284A1
Provided here are novel engineered and isolated signal peptide sequences and compositions comprising these. Also provided are compositions and methods of using these signal peptides to enable secretion of heterologous polypeptides for therapeutic, diagnostic, and commercial value.
Resumen de: WO2024064800A2
Disclosed herein are lipid nanoparticles comprising plurality of lipids, a targeting moiety for an HIV-1 chemokine receptor, and a CRISPR nucleic acid complementary to an HIV-1 gene, pharmaceutical compositions and methods of use thereof.
Resumen de: WO2024064206A1
This disclosure relates to lipid nanoparticles comprising nucleic acids encoding therapeutic proteins and uses in treating diseases such as cancer. In certain embodiments, this disclosure relates to methods of treating cancer or initiating, enhancing, or prolonging an anti-tumor response in a subject in need thereof comprising administering to the subject an effective amount of lipid nanoparticles as reported herein comprising a vector or nucleic acid encoding peptide based anticancer agent.
Resumen de: EP4591856A1
The present disclosure relates to polymer nanoparticles of metabolites, a cell activity promotion method using same, and a cell activity promotion composition including same. In particular, the present disclosure relates to a method and a composition, for promoting, by the permeation of polymer nanoparticles of metabolites into cells, the activities of cells, for example, adhesion between cells or between tissues, hemostasis, wound healing promotion, hair root regeneration activity, and antibacterial activity.
Resumen de: EP4591859A1
The invention discloses a lipid nanoparticle and a preparation method and application thereof are provided. The lipid nanoparticle (LNP) includes a carrier and an encapsulated nucleic acid, the carrier includes an ionizable lipid, a helper phospholipid, a PEGylated lipid, cholesterol and its derivatives, and a retinoid compound; and the nucleic acid is one or more of mRNA, circRNA, siRNA, microRNA, antisense nucleic acid, and plasmid. The invention proves that the five-component LNP can activate the triple immune response of body fluid, cells and mucosa after intramuscular or subcutaneous administration, and has important application prospects in the field of infectious disease vaccines and mucosal-related tumor vaccines.
Resumen de: EP4591890A1
According to one arrangement, a radiotherapy lipid nanoparticle (10) includes a biodegradable lipid nanoparticle (11), and a radioactive material (12) as an active ingredient. The radioactive material is bound to the biodegradable lipid nanoparticle and located outside of the biodegradable lipid nanoparticle.
Resumen de: MX2025003345A
Disclosed is a lipid nanoparticle (LNP) encapsulating a nucleic acid cargo preferably comprising messenger ribonucleic acid (mRNA). The LNP comprises at least a cationic lipid fraction, and a stabilizer fraction. The stabilizer fraction preferably comprises at least one polyethylenglycol (PEG) lipid. Furthermore, the LNP comprises at least one glycerol dialkyl glycerol tetraether (GDGT) lipid, as obtained e.g. from archaea of the genus Sulfolobus, optionally among other ether lipids. Also disclosed is a pharmaceutical composition comprising the LNP, such as an mRNA vaccine.
Resumen de: WO2024062127A1
Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic/injured area).
Resumen de: WO2024061861A1
The present invention relates to a composition comprising a solid carrier, an enzyme or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the enzyme or the fragment thereof by embedding the enzyme or the fragment thereof, and a functional constituent immobilized on the surface of the protective layer. The present invention also relates to a method for the prevention, delay of progression or treatment of lung cancer in a subject using said composition and methods of producing said composition.
Resumen de: AU2023347083A1
This disclosure relates to RNA interference (RNAi) reagents for treatment of SARS-CoV-2 infection, compositions comprising same, and use thereof to treat or prevent infection by SARS- CoV-2.
Resumen de: CN120381439A
本发明涉及一种基于吡啶基卟啉的聚乙二醇化的纳米颗粒及其制备方法与应用。本发明的纳米颗粒为壳核结构的球形纳米颗粒；所述壳为脂质‑聚乙二醇双层结构；所述核为基于吡啶基卟啉的铂离子型化合物；所述基于吡啶基卟啉的铂离子型化合物通过吡啶醇类配体与PtCl2(PhCN)2混合制备得到。本发明通过将铂类药物与质子化卟啉通过离子对结合解决了传统铂类药物的诸多问题，主要包括提高了铂类药物的水溶性以及对肿瘤细胞的细胞毒性作用，实现了化学疗法和PDT疗法的协同抗癌作用。材料无需复杂的制备过程，操作简便，易于封装。
Resumen de: AU2023375897A1
Provided herein are circular RNA constructs comprising an IRES, and at least one expression sequence encoding binding molecule, compositions thereof, and methods of treatment, including for cancer and autoimmune disease. In particular, circular RNA comprising an IRES and a CD19 binder, a HER2 binder, or a BCMA binder are provided, optionally formulated with a delivery vehicle. Precursor polynucleotides comprising an IRES, and at least one expression sequence encoding a CAR construct are also described herein.
Resumen de: AU2023393613A1
The invention provides a lyophilized nucleic acid lipid nanoparticle (NALNP) comprising (a) a lipid nanoparticle comprising a nucleic acid, and (b) a lyophilization buffer comprising a sugar, a lyophilization reagent, and a pharmaceutically acceptable diluent, as well as a method of preparing same.
Resumen de: WO2024135604A1
The object of the present invention is to provide a method for delivering a therapeutic agent to endothelial cells, mesenchymal cells, or cancer cells which can realize excellent delivery efficiency to organs other than the liver, and a composition containing a therapeutic agent and lipid nanoparticles which can realize excellent delivery efficiency to an organ other than the liver. The present invention provides a method for delivering a therapeutic agent to endothelial cells, mesenchymal cells, or cancer cells, which comprises administering a lipid composition to a subject, wherein the lipid composition comprises the therapeutic agent and lipid nanoparticle, and wherein the lipid nanoparticle comprises an ionizable lipid and a compound represented by formula (1) or a salt thereof. (1) wherein G1 represents -C(O)-, -OC(O)-, -O(CO)O- or -C(O)O-, LY represents a single bond, an alkylene group having 1-14 carbon atoms, a substituted alkylene group having 1-14 carbon atoms, a heteroalkylene group having 1-14 carbon atoms, and a substituted heteroalkylene group having 1-14 carbon atoms. X represents a basic functional group.
Resumen de: CN120381516A
本发明公开了一种工程化强效树突状细胞疫苗及其制备方法与应用，利用纳米级抗原递送的方式，将肿瘤抗原与阳离子脂质体相融合，借助阳离子脂质电荷相互作用破坏溶酶体膜的稳定性，使部分抗原逃逸到细胞质中通过MHC I途径交叉呈递，给予DC以激活细胞免疫应答的能力对抗肿瘤；另一方面，通过合成免疫学的方法赋予DC以T细胞导向性，首先在DC表面修饰叠氮基团N3，在T细胞特异性抗体上修饰二苯并环辛炔基团DBCO，通过N3与DBCO的环加成反应将T细胞特异性抗体偶联到成熟DC表面，增加DC和T细胞接触的机会和持续时间，促进DC‑T细胞的相互作用和信号传递；两种机制的联合可克服现有DC疫苗反应率低的问题，实现抗肿瘤免疫响应的最大化。
Resumen de: CN120381441A
本发明公开了一种用于肿瘤靶向的自触发蛋白质水解及RNA干扰的纳米粒子及其制备方法与应用，属于生物医药技术领域。本发明的纳米粒子以铁蛋白为载体，其内包裹有能够上调线粒体铁转运蛋白的siRNA，表面修饰有E3连接酶配体和肿瘤靶向肽，其制备方法包括：通过Click反应将E3连接酶配体和肿瘤靶向肽修饰在铁蛋白表面；利用铁蛋白的pH依赖性解聚/重组特性，将siRNA装载到铁蛋白载体中，获得用于肿瘤靶向的自触发蛋白质水解及RNA干扰的纳米粒子。本发明的纳米粒子能有效躲避肝脏的清除，有效富集在肿瘤部位，通过破坏肿瘤细胞线粒体内铁稳态，诱导肿瘤细胞死亡，进而激活强大的抗肿瘤免疫，其可用于制备抗肿瘤药物。
Resumen de: CN120381429A
本发明公开了一种可溶性纳米微针及其制备方法和应用，涉及纳米微针领域。本发明在制备可溶性纳米微针时，将吡咯、苯甲醛、对羟基苯甲醛、1,6‑二溴己烷反应制得季铵化卟啉；将聚乳酸‑羟基乙酸共聚物、季铵化卟啉通过乳液法制得载药纳米微球；再将聚乙烯醇溶液、载药纳米微球通过模板法制得。本发明制备的可溶性纳米微针具有良好的药物释放效果，药物利用率高，且刺激性低。
Resumen de: CN120381531A
本发明涉及载药粒子技术领域，尤其涉及一种载药纳米粒子及金属多酚网络介导的可食源性组装体，将天然硫化物包覆在含有介孔结构的碳酸钙中形成所述载药纳米粒子，并将载药纳米粒子的外层包裹上具有金属‑多酚网络结构的纳米涂层，得到金属多酚网络介导的可食源性组装体，用于制备治疗酒精损伤的药物，所述药物有助于减轻酒精造成的组织损伤和行为障碍。
Resumen de: CN120381440A
本发明公开了具有pH响应性和肿瘤靶向性的siRNA递送载体CCM‑CS/ZnO@siSurvivin，公开了其制备方法，公开了其形态、结构等理化性质，公开了其包封率、释药行为，公开了其细胞摄取效率、肿瘤靶向能力、溶酶体逃逸能力、基因沉默效率、促凋亡能力、肿瘤细胞生长抑制能力，公开了Survivin siRNA和ZnO协同抗肿瘤能力，进一步公开了其体内靶向性以及抑制BALB/c荷瘤裸鼠肿瘤生长的作用和体内安全性。进而阐明了该靶向递送载体在肿瘤的基因治疗领域具有重要的应用。
Resumen de: CN120383729A
本发明涉及生物医药技术领域，尤其涉及一种用于器官选择性递送核酸药物的类脂质分子、类脂质纳米颗粒及其应用、类脂质纳米颗粒‑核酸复合物及其制备方法。本发明提供的类脂质分子是由聚乙烯亚胺与芳基丙烯酸酯发生迈克尔加成反应得到，合成方法简单安全，反应条件温和，成本低；所述类脂质纳米颗粒按质量百分比计由如下组分组成：类脂质分子30～80％，甾醇5～50％，聚乙二醇‑脂质5～40％，辅助脂质5～50％。本发明的优点在于通过调节类脂质分子自身的化学结构实现了其类脂质纳米颗粒在受试生物体内对核酸药物的器官选择性递送。
Resumen de: CN120383680A
本发明公开了一种高效降解目标蛋白的PROTAC及其制备和递送方法，将相分离序列与设计的双靶向分子融合，分别靶向目标蛋白以及蛋白酶体，实现PROTAC与目标蛋白的相分离，从而实现目标蛋白的高效降解。通过LNP包封mRNA也实现了PROTAC的递送，同样可以在细胞内高效降解目标蛋白，这也为肽类或蛋白类PROTAC向人体内的递送提供了一种途径。
Resumen de: WO2024112882A1
The present invention relates to compositions for effective delivery of gene editing agents to a target cell, as well as methods of use thereof for the treatment of a disease or disorder.
Resumen de: MX2025006877A
The present invention relates to a messenger RNA (mRNA)-based immunogenic composition that is capable of inducing a mammalian cell to produce an influenza virus-like particle (VLP). The immunogenic composition comprises one or more mRNAs encoding an influenza virus matrix 1 (M1) protein and one or more influenza virus hemagglutinin (HA) proteins and/or one or more influenza virus neuraminidase (NA) proteins.
Resumen de: WO2024098127A1
The present invention describes nanostructured lipid systems containing the antibiotic besifloxacin and the application thereof in the treatment and prevention of bacterial eye infections. Besifloxacin, an antibiotic with low aqueous solubility, is encapsulated in a nanostructured lipid system comprising a solid lipid, a liquid lipid, a surfactant and a co-surfactant. Optionally, the system of the invention can be additionally coated with an antibacterial cationic agent. The nanostructured lipid system according to the invention allows the topical administration of besifloxacin in the eyes and gives the drug a longer retention time on the surface of the eye. Furthermore, the system described herein is designed using industrially applicable methods and remains stable under storage conditions for at least 90 days, so it can be readily reproduced on an industrial scale.
Resumen de: CN120361244A
本发明公开了一种电诱导辅助制备的营养递送体系及其制备方法和应用，制备方法为：将两亲性成壳蛋白和脂溶性的包埋物分别溶于溶剂A中，得到包埋物/两亲性成壳蛋白溶液，将其滴加到溶剂B或壳聚糖的C溶液中，所述壳聚糖溶液由壳聚糖溶解到溶剂C中得到，在滴加过程中通入40V，100mA的持续电流，包埋物/两亲性成壳蛋白在溶剂A或溶剂C中析出，负压蒸发，调节pH值，得到电诱导辅助制备的载包埋物的两亲性成壳蛋白基纳米颗粒或两亲性成壳蛋白基‑壳聚糖纳米颗粒，两者均为核壳结构，包埋物为核，两亲性成壳蛋白或被壳聚糖修饰的两亲性成壳蛋白为壳。本发明采用电诱导法辅助制备营养递送体系具有简便高效，反应条件温和，无毒副作用等特点。
Resumen de: US2025230471A1
The present disclosure provides compositions and methods for inserting heterologous payload sequences into a target-site in a host cell genome. The compositions and methods use non-LTR retrotransposon reverse transcriptase proteins that bind template RNAs comprising a payload sequence that encodes a protein or regulatory RNA. The template RNA can comprise modified uridines that are not cleavable by a ribozyme. The incorporation of modified uridines increases the efficiency of integration and expression of the payload sequence and decreases cellular toxicity.
Resumen de: CN120361008A
本发明提供了基于米尔贝肟吡喹酮的寄生虫驱除药物，以质量份计，所述药物包括以下组分：改性米尔贝肟10‑30份、纳米包覆吡喹酮20‑50份、复配增效剂5‑15份、矫味剂3‑8份、崩解剂2‑5份。基于米尔贝肟吡喹酮的寄生虫驱除药物的应用，所述药物用于制备预防或治疗犬、猫的混合寄生虫感染的制剂，所述寄生虫包括绦虫、线虫、吸虫及蠕形螨。本申请通过化学改性（琥珀酰化米尔贝肟）、纳米技术（HPMC包覆吡喹酮）、复配协同（非班太尔‑β环糊精）的集成创新，实现广谱驱虫、长效稳定、安全低毒的综合优势，同时解决现有技术中适口性差、代谢负担高、环境适应性弱等痛点，适用于犬猫混合寄生虫感染的预防与治疗。
Resumen de: CN120364654A
本申请提供了一种红色纳米硒颗粒的制备方法及其应用，涉及纳米医药技术领域，制备方法包括将亚硒酸钠溶于超纯水，加入含铜锌铝硅酸盐微球，pH至4.8，搅拌滴加1.5M抗坏血酸溶液，升温至加入固体抗坏血酸，用NaOH调节pH，搅拌反应得到纳米硒悬浮液；将纳米硒悬浮液、海藻酸钠巯基氧化石墨烯混合物和壳寡糖柠檬酸缓冲液混合搅拌，离心洗涤后冷冻干燥，得到红色纳米硒颗粒，所述含铜锌铝硅酸盐微球通过介孔模板煅烧及铜锌共掺杂制备，用该方法制备出的红色纳米硒颗粒具有核壳结构，粒径均一且抗氧化性强的同时具有显著的界面结合强度。
Resumen de: US2024245618A1
The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
Resumen de: WO2024177578A1
A method of producing a biomolecule-crosslinked compound is disclosed. More specifically, the method comprises the steps of reacting a plurality of monomers and a plurality of comonomers in the presence of ammonia within a first solution to generate a compound; retrieving the produced compound from the first solution for cleaning; subjecting the cleaned compound to react with a second solution to join a crosslinker onto the compound through a first amine functional group of the crosslinker; and adding a plurality of biomolecules to the second solution to bind the biomolecules towards the compound through a second amine functional group of the crosslinker to produce the biomolecule-crosslinked compound.
Resumen de: CN120361109A
本发明涉及一种去腐生肌抗感染药膏及其制备方法，属于中药技术领域。本发明以地榆、黄连、黄柏、黄芩、虎杖、紫草、冰片、蜂蜡、香油为基础原料制备去腐生肌抗感染药膏；将地榆提取物制成pH响应纳米粒和紫草提取物制成紫草提取物‑硫辛酸复合物靶向坏死组织释放活性物质，促进坏死组织的自然去除，同时保护健康组织。
Resumen de: AU2023408183A1
Aspects of the disclosure relate to compositions and methods for improving the stability of lipid nanoparticles (LNPs). In some embodiments, the LNPs comprise one or more active pharmaceutical ingredients (API) encapsulated therein. The disclosure is based, in part, on compositions that directly or indirectly reduce the degradation (e.g., oxidation, hydrolysis, etc.) of one or more lipids components of the lipid nanoparticle. In some embodiments, the compositions comprise a histidine buffer. The disclosure also provides methods for storing compositions contemplated herein as well as methods for improving the stability of the API.
Resumen de: WO2025153097A1
The use of blank lipid nanoparticles in the preparation of an in-vivo delivery product, comprising the step of mixing the blank lipid nanoparticles with a biologically active substance in a solvent to obtain a blank lipid nanoparticle-based composition. The blank lipid nanoparticles consist of an ionizable lipid, a phospholipid, a steroid or a derivative thereof, and a polyethylene glycol-lipid conjugate. According to the blank lipid nanoparticles, the dosage of the biologically active substance can be flexibly adjusted according to the requirements of a user, and the blank lipid nanoparticles can be administered via multiple routes such as intravenous injection, intramuscular injection, intraperitoneal injection, and subcutaneous injection, all of which can achieve an ideal delivery effect.
Resumen de: CN120360968A
本申请提供一种麦角甾醇纳米分散体及其制备方法和应用，麦角甾醇纳米分散体包括麦角甾醇芯材和包裹所述麦角甾醇芯材至少部分表面的大豆分离蛋白壁材，所述分散体的粒径为250‑400 nm，所述分散体的PDI为0.034‑0.106。该分散体特殊的组成及相关参数，显著改善了麦角甾醇在水中的分散性、均一性和生物可及性。
Resumen de: CN120361241A
本发明涉及一种白蛋白功能化硫化钽纳米点在制备治疗急性肾损伤药物中的应用，属于纳米药物新用途技术领域。本发明所用的白蛋白功能化硫化钽纳米点由安全无毒且无免疫原性的理想载体白蛋白和高生物相容的层状过渡金属硫化钽简单高效组装而成；能够凭借其超小粒径穿越肾小球滤过屏障特异性蓄积于肾脏，利用白蛋白与巨蛋白受体的特异性结合主动内化至近端小管上皮细胞，又依赖白蛋白对线粒体的高亲和力序贯定位至线粒体。该纳米点在急性肾损伤病理损伤微环境中通过钽离子活跃的价态变化高效清除活性氧并保护线粒体，限制细胞凋亡、免疫激活及无菌性炎症，进而实现近端小管上皮细胞损伤缓解并有效恢复肾脏功能。
Resumen de: CN120360969A
本发明公开了双靶向巨噬细胞膜纳米系统及其制备方法与应用，属于生物医药领域，MKA由AuNPs与线粒体靶向肽KLA连接后包裹于巨噬细胞膜内。制备时先合成AuNPs并修饰，再用巨噬细胞膜包裹。在治疗中，它能双靶向肿瘤细胞和线粒体，增强辐射诱导的DNA损伤，抑制DDR，激活免疫通路，促进T细胞浸润，还可消耗谷胱甘肽、放大氧化应激来增强免疫效果，与8GyX射线协同的剂量增强比达3.1。此外，MKA在体内生物相容性良好，血液循环时间长、肿瘤靶向性高且能快速经肾脏清除。该发明为肿瘤放射免疫治疗提供新途径，有助于推动临床肿瘤治疗的进步。
Resumen de: CN120360965A
本发明公开了一种基于多酚氧化偶联自组装的pH响应性口服纳米药物及其制备方法和应用。该纳米药物设计简单高效，本发明所述的纳米药物是基于多酚在酸性介质中通过氧化剂介导的氧化偶联自组装，提供了一种耐酸不耐碱的pH响应性口服递送载体。通过溶剂转换介导的解组装‑重组装作用，高效负载疏水性药物，制备得到口服纳米药物。本纳米策略极大的提高了疏水性药物的载药率，载药量高达50％。同时避免了纳米药物被恶劣的胃生理环境破坏，靶向肠道递送。基于生物活性的多酚载体与药物之间的双重抗炎抗氧化作用，该口服纳米药物能够作为优异的多功能药物制剂通过协同作用预防或治疗炎症性肠病。
Resumen de: CN120360189A
本发明公开了一种幼鹅养殖饲料，属于养殖饲料技术领域，来解决现有改进型饲料仍存在配方复杂、成本高、效果不稳定的问题，能量原料占55‑68%，优选62%；蛋白原料占22‑30%，优选26%；预混料占5‑8%，优选6.5%；功能添加剂占3‑7%，优选5.5%，通过复合酶制剂与微生态制剂的协同作用，显著提高了粗蛋白消化率，使其提升至78.6%（P＜0.01），有效提高了饲料的利用效率，利用纳米包被技术形成的缓释体系，使维生素D3半衰期延长至48小时，持续为幼鹅提供稳定的维生素D3来源，促进钙、磷吸收和骨骼发育，根据幼鹅不同生长阶段对钙、磷的需求，将钙磷比在1.8:1‑2.2:1进行梯度调整，满足幼鹅骨骼发育和新陈代谢的需求，减少因钙磷失衡导致的疾病。
Resumen de: CN120361235A
本发明提供了一种双靶向类载体材料、制备方法、及其包裹的齐墩果酸纳米粒的制备方法，属于医药技术领域。以双靶向性的高分子共聚物为载体材料，采用乳化‑溶剂挥发法制备齐墩果酸靶向纳米粒，能够保护齐墩果酸不被快速降解，延长其在体内的循环时间。同时，通过靶向基团，实现对齐墩果酸的靶向递送，提高药物在肿瘤组织的浓度，降低对正常组织的毒副作用。采用MTT法，研究齐墩果酸纳米粒对细胞生长的抑制作用，结果显示，齐墩果酸靶向纳米粒具有相对于齐墩果酸原料药具有更强的抑制肿瘤细胞增殖的作用。
Resumen de: US2025235524A1
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of ribonucleic acid immunogenic compositions and/or vaccines comprising polynucleotide molecules preferably encoding one or more influenza antigens, such as hemagglutinin antigens, wherein the composition is frozen or lyophilized.
Resumen de: US2025235525A1
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
Resumen de: US2025236645A1
This present disclosure provides RNA expression systems based on sequences from plant viruses, insect viruses, and flaviviruses that eliminate the need for expensive modifications. Methods to express and package an RNA polynucleotide without the need for in vitro transcription and lipid nanoparticles are provided. Also provided are methods to package an RNA polynucleotide using synthetic polyanhydride nanoparticles that are stable at room temperature and suitable for delivery by nasal spray.
Resumen de: US2025236599A1
The current invention relates to ionizable lipid-like compound according to Formula (I) or pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.The present invention also provides a lipid nanoparticle comprising an ionizable lipid-like compound according to Formula I and one or more RNA molecules, as well as a pharmaceutical composition or vaccine, comprising such lipid nanoparticles.
Resumen de: US2025235500A1
Disclosed in the present invention are a new polypeptide for promoting tissue repair, and the use thereof. The new polypeptide can promote the proliferation of human immortalized epidermal cells and the migration of human epidermal fibroblasts at a relatively low concentration, can promote the repair of wounds and ulcers, improves the aesthetic feeling of the skin, has low toxic side effects, has good application prospects, and can be used for preparing a drug and a medical instrument for treating wound surfaces, scalds and ulcers or for preparing an everyday chemical for improving the aesthetic feeling of the skin.
Resumen de: US2025235411A1
The present disclosure provides lipid nanoparticle compositions and methods of use. Among other things the present disclosure provides lipid nanoparticle compositions which increased specificity for specific cells or tissues. The present disclosure provides methods of use of the disclosed lipid nanoparticles.
Resumen de: AU2024207086A1
A miRNA-mimic based therapeutic particle is disclosed herein. The particles comprise a synthetic miRNA or mimic of miR-187-3p encapsulated in a lipid nanoparticle (LNP) carrier or synthetic miR-193b-5p inhibitor encapsulated in a lipid carrier or their combination encapsulated in a lipid carrier. The lipid nanoparticle carrier is made up of at least four (4) types of lipids, in which the four (4) types of lipids include a) an ionizable cationic lipid selected to be positively charged in a formulation buffer (pH 4), which binds and protects the negatively charged miRNA, and facilitates endosomal escape, and is neutral in a storage buffer, b) a sterol in the structure of the lipid nanoparticle (LNP)., c) a structural helper lipid selected to contribute to lipid nanoparticle stability and/or enhances endosomal release, and d) a PEGylated-lipid selected such that it stabilizes the therapeutic particle and protects it from opsonization.
Resumen de: AU2025204994A1
Compositions and methods for delivering non-anionic polynucleotide analog cargoes to the cytosolic/nuclear compartment of eukaryotic cells via a synthetic peptide shuttle agent are described herein. The non-anionic polynucleotide analog cargoes may be charge-neutral or cationic, and the synthetic peptide shuttle agent is a peptide comprising an amphipathic alpha-helical motif having both a 5 positively-charged hydrophilic outer face and a hydrophobic outer face, wherein synthetic peptide shuttle agent is not covalently linked, or linked in a cleavable manner under physiological conditions, to the non- anionic polynucleotide analog cargoes. The non-anionic polynucleotide analog cargo may be a charge- neutral or cationic antisense synthetic oligonucleotide (ASO) that hybridizes to an intracellular target RNA for gene expression modification. 10 Compositions and methods for delivering non-anionic polynucleotide analog cargoes to the cytosolic/nuclear compartment of eukaryotic cells via a synthetic peptide shuttle agent are described herein. The non-anionic polynucleotide analog cargoes may be charge-neutral or cationic, and the 5 synthetic peptide shuttle agent is a peptide comprising an amphipathic alpha-helical motif having both a positively-charged hydrophilic outer face and a hydrophobic outer face, wherein synthetic peptide shuttle agent is not covalently linked, or linked in a cleavable manner under physiological conditions, to the non- anionic polynucleotide analog cargoe
Resumen de: AU2023410864A1
The invention provides a composition, e.g., in the form of a powder, comprising chitosan particles. The invention also provides method for treating an oral condition in a patient by administering to the patient a composition of the invention to treat the oral condition. The invention further provides devices suitable for administering the composition.
Resumen de: WO2025153768A1
The disclosure relates to a composition comprising nanoparticles of crystalline apalutamide and polyvinylpyrrolidone/vinyl acetate (PVPVA) and/or hydroxypropyl methyl cellulose (HPMC). The disclosure also relates to a method for producing the composition.
Resumen de: WO2025155926A1
The present technology provides methods of reducing vein graft injury comprising administering an effective amount of a bioavailable nanoparticle comprising NAD+ and/or NADH to the vein to be grafted prior to surgical implantation of the vein graft in a subject. Additionally, the present technology provides methods of improving vein graft health and preventing or treating post-operative restenosis and also provides bioavailable nanoparticles comprising NAD+ and/or NADH and a coating comprising a human cell membrane for use in such methods.
Resumen de: WO2025155929A1
The present technology provides methods of reducing ischemia-reperfusion (IR) injury in a kidney to be transplanted comprising administering an effective amount of a bioavailable nanoparticle comprising NAD+ and/or NADH to the kidney prior to surgical transplantation of the kidney into a subject. Additionally, the present technology provides methods of reducing ischemia-reperfusion (IR) injury to a transplanted kidney in a subject comprising administering an effective amount of a bioavailable nanoparticle comprising NAD+ and/or NADH to the subject after transplantation of the kidney into the subject and also provides bioavailable nanoparticles comprising NAD+ and/or NADH for use in such methods.
Resumen de: WO2025155702A1
Adjuvant compositions, and vaccine compositions utilizing the adjuvant compositions, are described. The adjuvant compositions include a salt-crosslinked TEMPO-oxidized cellulose nanofibril (CNF) hydrogel, and the vaccine compositions further include an antigen or immunogen.
Resumen de: WO2025155087A1
The present invention relates to a microfluidic device for preparing lipid nanoparticles that can deliver nucleic acids, and a lipid nanoparticle preparation method using same. By using the microfluidic device, lipid nanoparticles of a desired size can be prepared by adjusting the molar ratio between compositions and the Reynolds number.
Resumen de: WO2025155269A1
The invention relates to serum containing encapsulated niaouli essential oil. In the preparation of said serum, firstly niaouli essential oil is encapsulated and then the obtained micro/nanoparticles are loaded into the serum carrier system. The serum containing encapsulated niaouli essential oil, which is the subject of the invention, contains olive oil, caprylic/capric triglyceride, cyclopentasiloxane, isopropyl myristate and encapsulated niaoulii essential oil. The serum containing encapsulated niaouli essential oil is used as a new alternative treatment method for eczema treatment.
Resumen de: WO2025153098A1
A pulmonary delivery system containing an ionizable lipid, and a preparation method therefor and the use thereof, which belong to the technical field of biomedicine. The pulmonary delivery system containing an ionizable lipid comprises an ionizable lipid, an auxiliary lipid, and a bioactive substance, and does not contain polymer-lipid conjugates. The pulmonary delivery system containing an ionizable lipid can deliver the bioactive substance to the lungs. The pulmonary delivery system has the characteristics of uniform particle size and high safety, and can efficiently deliver a therapeutic agent to the lungs. Before and after atomization, the particle properties such as the particle size, particle size distribution coefficient, potential, and encapsulation efficiency remain unchanged. The pulmonary delivery system provides a safe and effective solution for the treatment of pulmonary diseases, and has broad application prospects.
Resumen de: WO2025153099A1
The use of a prefabricated carrier in the preparation of a product for in vitro delivery of a gene into immune cells and stem cells, which belongs to the technical field of biomedicine. The use of a prefabricated carrier in the preparation of a product for in vitro delivery of a gene into immune cells and stem cells comprises the step of mixing the prefabricated carrier with a nucleic acid in a solvent to obtain a composition based on the prefabricated carrier. The composition of the prefabricated carrier comprises: an ionizable lipid, a phospholipid, a steroid or a derivative thereof, and a polyethylene glycol-conjugated lipid. The prefabricated carrier can be used as a carrier tool for cell and gene therapy.
Resumen de: WO2025153097A1
The use of blank lipid nanoparticles in the preparation of an in-vivo delivery product, comprising the step of mixing the blank lipid nanoparticles with a biologically active substance in a solvent to obtain a blank lipid nanoparticle-based composition. The blank lipid nanoparticles consist of an ionizable lipid, a phospholipid, a steroid or a derivative thereof, and a polyethylene glycol-lipid conjugate. According to the blank lipid nanoparticles, the dosage of the biologically active substance can be flexibly adjusted according to the requirements of a user, and the blank lipid nanoparticles can be administered via multiple routes such as intravenous injection, intramuscular injection, intraperitoneal injection, and subcutaneous injection, all of which can achieve an ideal delivery effect.
Resumen de: WO2025153095A1
A lipid composition and a preparation method therefor and the use thereof. The lipid composition comprises the following components: an ionizable lipid and an auxiliary lipid, and does not contain a component having a preventive or therapeutic effect. The lipid composition can be used for delivering nucleic acids, macromolecular substances and small molecular substances, has a good stability, can be stored at room temperature for a long time, and can be used as a carrier in multiple fields such as cell and disease treatment and prevention.
Resumen de: WO2025152109A1
A nano abiraterone acetate composition, a preparation method therefor, and an oral tablet thereof. The composition comprises abiraterone acetate, a suspending aid, a surfactant, and a stabilizer in percentage by weight of 1:(0.1-4):(6-20):(0.01-0.1), and is prepared by wet grinding, drying, and dewatering. The oral bioavailability of the product is improved by adding a cholate absorption-promoting agent, such that the influence of food on drug absorption is reduced.
Resumen de: US2025235412A1
A poly(beta-aminoester) polymer of formula (I) or a pharmaceutically salt thereof which comprises one or more zwitterionic polymers. Advantageously, the polymer of the invention shows improved properties when formulated in the form of nanoparticles. Processes for the preparation of the polymer, nanoparticles comprising a polymer of Formula (I) and uses thereof.
Resumen de: US2025235404A1
Disclosed herein are polyethylene glycol (PEG)-lipids, functionalized PEG-lipids, and functionalized PEG-lipids that are conjugated to a binding moiety which can comprise an antibody antigen binding domain. Also disclosed are methods for synthesizing and functionalizing the PEG-lipids. The PEG-lipids are useful components lipid nanoparticles (LNP) used for the delivery of nucleic acids into living cells, in vivo or ex vivo. LNP comprising functionalized PEG-lipids that are conjugated to a binding moiety are useful as targeted LNP for delivering nucleic acids into cells or tissues expressing the ligand of the binding moiety.
Resumen de: US2025235394A1
Nanoparticles for treating a tooth in an oral cavity of a subject are provided. The nanoparticle comprises a biocompatible and biodegradable hydrophilic polymer, a matrix-degrading enzyme, and an anticaries active ingredient present in the nanoparticle at greater than or equal to about 20% by weight. The nanoparticle has a zeta potential between about −10 mV to about +10 mV at a pH of 7. The nanoparticle is capable of selectively accumulating within a biofilm matrix associated with a surface of the tooth in the oral cavity of the subject. Oral care composition and methods of treating a tooth in an oral cavity of a subject with such nanoparticles are also provided.
Resumen de: US2025235405A1
A nanoparticulate composition comprising a core comprising a therapeutically active agent selected from a nucleic acid, protein or peptide packaged within a non-viral drug delivery vehicle is described. The core comprises a low molecular weight stabilizing agent comprising at least one atom or group that is charged in aqueous solution, wherein when the therapeutic agent is negatively charged the charged atom or group is positively charged in aqueous solution and when the therapeutic agent is positively charged the charged atom or group is negatively charged in aqueous solution.
Resumen de: US2025235400A1
The disclosure provides a nanoemulsion including an oil phase containing at least one cannabinoid and a water phase; wherein at least one of the oil phase and the water phase includes one or more emulsifying agents; and wherein the zeta potential of the nanoemulsion is less than about −10 mV. Further provided are processes for preparing such nanoemulsions.
Resumen de: US2025235401A1
An oil in water nanoemulsion has an oil phase and an aqueous phase and comprises active pharmaceutical ingredient (API), edible oil, denatured plant protein, surfactant, and water, in which the API is contained in the oil phase. The API comprises an RNA molecule or a hydrophobic drug. The oil is high oleic oil. The oil in water nanoemulsion may be combined with a suspension of denatured plant protein and a calcium salt chelating agent to form microparticles or microcapsules comprising the nanoemulsion or the oil droplets of the nanoemulsion encapsulated within a denatured plant protein matrix. The microcapsules can be ingested orally and pass through the stomach to the ileum where the protein matrix breaks down to release the oil droplets containing the API, which is then absorbed.
Resumen de: US2025235403A1
Disclosed herein are pH-sensitive nanoemulsions as well as methods of using thereof. These pH-sensitive nanoemulsions can comprise a lipid particle encapsulating an active agent. The lipid particle can comprise one or more ionizable lipids; one or more neutral lipids; one or more PEGylated lipids; and optionally one or more fusogenic oils. In some embodiments, these compositions can be buffered at an acidic pH (e.g., a pH of less than 6.5, such as a pH of from 4 to 6.5, or a pH of from 5.0 to 6.5). By buffering at an acidic pH, the delivery efficiency of the compositions can be enhanced as compared to otherwise identical compositions buffered at a pH of 7 or more.
Resumen de: US2025235402A1
An aqueous, intra-oral, nanoemulsion blend is provided that enhances mitochondrial performance in mammals when orally administered. The blend includes at least two different monolayer surfactant bound particle components and at least one bilayer water-core liposome component. The blend optionally may include a micelle.
Resumen de: US2025235537A1
Methods for targeted therapy are disclosed. In certain embodiments, a method includes injecting nanoparticles into a target site in or adjacent to an eye, irradiating the target site with light from a light source, and activating the nanoparticles with the light.
Resumen de: US2025235532A1
The present invention relates to a polymer-lipid hybrid nanoparticle comprising a lipid and a block copolymer, wherein the amount of said lipid, expressed in mole percentage (mole %) present in the polymer-lipid hybrid nanoparticle, wherein the mole percentage refers to the total amount of all components that form the polymer-lipid nanoparticle, is greater than the amount of said block copolymer, expressed in mole percentage, present in the polymer-lipid hybrid nanoparticle. The invention also relates to such a polymer-lipid hybrid nanoparticle further comprising a soluble encapsulated antigen, wherein said soluble encapsulated antigen is a protein and/or polynucleotide. The invention further relates to a method of encapsulating such an antigen in such a polymer-lipid hybrid nanoparticle as well as to a composition comprising such a polymer-lipid hybrid nanoparticle and uses of such a polymer-lipid hybrid nanoparticle and/or composition as a vaccine, a pharmaceutical, means of targeting cells, tissues and/or organs and/or non-viral delivery system capable of delivering nucleotides to inside a cell.
Resumen de: US2025235531A1
The present disclosure provides compositions and methods for the preparation, manufacture, and therapeutic use of lipid nanoparticles comprising nucleic acid vaccines, e.g., mRNA vaccines, for delivery to mucosal surfaces.
Resumen de: US2025235551A1
Porous microcarriers prepared from a poly(lactide-co-glycolide) and a porogen, which are suitable for loading of therapeutic lipid nanoparticles into the pores thereof.
Resumen de: US2025236585A1
The present invention provides an ionizable lipid compound, which can target spleen for delivery of biological macromolecules including nucleic acid drugs or nucleic acid vaccines with high efficiency. The present invention also relates to a lipid nanoparticle (LNP) comprising the ionizable lipid compound and an active molecule, and a pharmaceutical composition comprising the lipid nanoparticle.
Resumen de: EP4588910A1
Provided in the present invention are long-acting low-toxicity novel cationic lipid compounds, which are compounds shown as formula (I), or N-oxides, solvates, pharmaceutically acceptable salts or stereoisomers thereof. Further provided are a composition comprising the compounds and the use thereof for the delivery of therapeutic or prophylactic agents.
Resumen de: MX2025002927A
The present disclosure relates to a method for treating cancer in a subject that is BRCA-negative and homologous repair proficient (HRP), the method comprising administering to the subject a nucleic acid vector (e.g., a plasmid) comprising a polynucleotide that encodes an interleukin-12 (IL-12) formulated with a lipopolymer (e.g., a nanoparticle). In some aspects, the method further comprises administering to the subject an anticancer agent (e.g., a chemotherapeutic agent), an antibody or antigen-binding fragment thereof that specifically binds a vascular endothelial growth factor (VEGF) (anti-VEGF antibody), an immune checkpoint inhibitor, or any combination thereof.
Resumen de: MX2025002695A
Generally, a polymer nanomaterial encapsulation system useful in the production of polymer encapsulated nanoparticles comprised of a hydrophobic nanoparticle encapsulated in the hydrophobic region of the polymer with the external hydrophilic region of the polymer ensuring water-solubility and affording a functional group which can be utilized for the production of nanoparticle conjugates. Specifically, particular embodiments include a polymer nanoparticle structure including one or more of: a quantum dot and/or a superparamagnetic iron oxide nanoparticle and/or an upconverting nanoparticle, encapsulated in polystyrene-b-polyethylene glycol amine for the production of antibody conjugates useful in the capture of cellular targets.
Resumen de: WO2024058718A1
A heart valve prosthesis with one or more drug eluting mechanisms embedded in the prosthesis during manufacture.
Resumen de: MX2025002919A
Compounds, compositions, uses, and methods for reducing cell viability of a cancer cell, or for preventing or treating cancer, are provided herein. In certain examples, methods for reducing cell viability of a cancer cell and/or for preventing or treating cancer in a subject in need thereof are provided which may include a step of treatment with a GDP-bound form of Rab1a (Rab1a<sup>GDP</sup>), one or more expressible nucleic acids encoding Rab1a<sup>GDP</sup>, or a combination thereof.
Resumen de: MX2024015894A
The present invention is directed to lipid nanoparticles using cationic cholesterol for topical delivery for nucleic acid delivery, and when administered locally, side effects caused by systemic drug delivery can be minimized and protein expression can be confined to the site of administration. In addition, the duration of protein expression at the site of administration can be increased, and thus the lipid nanoparticles can be useful in the technical field related to nucleic acid therapeutics.
Resumen de: US2024245618A1
The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
Resumen de: CN119055798A
Provided herein are methods comprising introducing a therapeutically effective amount of an adeno-associated virus (AAV) vector into the inner ear of a mammal, the AAV vector comprises a nucleotide sequence encoding the following polypeptides: (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide comprising an antigen binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to the signal peptide.
Resumen de: US2024009131A1
The disclosure features novel methods of producing nucleic acid lipid nanoparticle (LNP) compositions employing a modifying agent after formation of a precursor nucleic acid lipid nanoparticle, the produced compositions thereof, and methods involving the nucleic acid lipid nanoparticles useful in the delivery of therapeutics and/or prophylactics, such as a nucleic acid, to mammalian cells or organs to, for example, to regulate polypeptide, protein, or gene expression.
Resumen de: MX2024015149A
Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (<i>e.g</i>., immune cells), and methods of making and using such lipids and targeted lipid nanoparticles.
Resumen de: CN119173498A
The present disclosure relates to novel lipids, nanoparticles comprising such lipids and their use for delivering therapeutic agents to a subject or treating and/or preventing a disease in the subject.
Resumen de: WO2024057039A1
The present invention relates to a method of treatment wherein a composition comprising a cannabinoid and an amphiphilic carbohydrate compound such as GCPQ is administered intranasally. The method of treatment is particularly suitable for use in central nervous system disorders. The invention further relates to the composition when formulated with other components in pharmaceutical compositions for use in therapy.
Resumen de: CN120346178A
本发明涉及一种负载雷帕霉素的仿生纳米颗粒及其制备方法与应用。本发明负载雷帕霉素的仿生纳米颗粒包括负载雷帕霉素的RZ NPs和肿瘤细胞膜；所述肿瘤细胞膜包覆负载雷帕霉素的RZ NPs；所述雷帕霉素修饰于RZ NPs的孔隙中；所述RZ NPs具有ZIF8的晶体结构。本发明的负载雷帕霉素的仿生纳米颗粒的制备方法包括负载雷帕霉素的RZ NPs的制备和用肿瘤细胞膜对RZ NPs进行修饰制备RZM NPs。本发明的RZM NPs对肿瘤具有外照射增敏的能力，由于雷帕霉素对于细胞周期具有潜在的影响可能性，能够使得肿瘤细胞停滞在对外照射更敏感的阶段从而提高放疗效果。
Resumen de: CN120349253A
本发明提供了一种完全生物可降解的可电离脂质化合物，该化合物具有如下所示的结构。该化合物可与其它脂质化合物共同制备脂质纳米颗粒，对核酸药物的包封效率高，且可在生物体内完全降解，安全性较好，适合应用于核酸药物递送、核酸疫苗、核酸治疗性药物等。#imgabs0#
Resumen de: CN120346179A
本发明属于生物技术和皮克林乳液制备技术领域，具体公开了一种微流控制备并原位包载香芹酚的卵白蛋白纳米粒的方法及其稳定的皮克林乳液。本发明制备纳米粒的方法较为方便且制备的纳米粒粒径小，简单易行，重复性高，制备速度快、效率高。且本发明利用原位加热处理后的香芹酚‑卵白蛋白纳米粒(OVA‑Car NPs)作为稳定剂制备皮克林乳液，所涉及的方法简单，制备的乳液稳定性高；可用于负载及保护香芹酚和木犀草素，提高香芹酚以及木犀草素的存储稳定性，改善了两者的使用局限性，使两者在抗菌领域有了更广阔的应用前景。
Resumen de: CN120346174A
本发明公开了一种白蛋白mRNA肠溶胶囊及其应用，本发明首次提出基于LNP冻干胶囊的口服肠道递送白蛋白mRNA的创新治疗策略，诱导机体自主合成功能性白蛋白，该方案突破了传统输注疗法的局限性，同时规避了mRNA疗法的长期生物安全风险，为低蛋白血症的治疗提供了全新的治疗方案和治疗策略。
Resumen de: CN120346180A
本发明属于肠道菌群处理技术领域，具体地涉及一种基于PDA@Fe3O4纳米颗粒的肠道菌群包埋工艺及其应用，该包埋工艺是将肠道菌群制成菌泥后加入到PDA@Fe3O4纳米颗粒悬浮液中，经孵育、离心后得到PDA@Fe3O4纳米颗粒包埋后的肠道菌群菌泥。本发明包埋工艺简单易行，提升了肠道菌群在胃肠道环境中的存活率和功能性，降低了患者服用的安全隐患及风险，增强了生物相容性，可应用于开发肠道菌群移植技术及能耐胃肠液的肠道菌群功能药物中。
Resumen de: WO2024131717A1
The present invention relates to the field of biological medicines, in particular to cationic lipid compounds capable of being used for nucleic acid delivery, a preparation method therefor and the use thereof. LNPs prepared from the cationic lipid compounds having novel structures have the advantages of high transfection efficiency, etc., and in particular, the LNPs are distributed only at injection sites.
Resumen de: US2025195447A1
A novel biomimetic nano-sphere M@P-WI includes PLGA nanoparticles and the membrane of breast cancer EO771 cells. The PLGA nanoparticles are encapsulated within the membrane of breast cancer EO771 cells, and IR780 and DDR2 inhibitor WRG-28 are embedded in the PLGA nanoparticles. A method for preparing and applying the novel biomimetic nano-sphere M@P-WI is also provided. The method utilizes the aforementioned novel biomimetic nano-sphere M@P-WI, to trigger the conversion of light into heat energy upon near-infrared laser irradiation. This “burns” the tumor and induces specific immune responses within the body, inhibiting tumor recurrence and metastasis. Under the action of WRG-28, it promotes apoptosis of cancer-associated fibroblasts (CAF), reduces the remodeling of tumor extracellular matrix microenvironment, enhances the distribution of nanomaterials within the tumor, and restricts the invasiveness of breast cancer cells. With laser irradiation, the photosensitizer exhibits its maximum efficacy, achieving complete elimination of TNBC rich in extracellular matrix.
Resumen de: CN120346183A
本发明涉及一种包载卡介苗裂解物的过表达PD‑1的细胞外囊泡及其制备方法和应用，本发明的方法包括以下步骤：1、对肿瘤细胞的转染和筛选构建PD‑1过表达肿瘤细胞系LLC/PD‑1；2、梯度离心法得到过表达PD‑1肿瘤细胞外囊泡LPV；3、卡介苗热灭活法制备卡介苗裂解物BL；4、将过表达PD‑1的肿瘤源性细胞外囊泡(TEVs)与卡介苗裂解物BL挤压制备载药囊泡LP@BLV。本发明将工程化过表达PD‑1的肿瘤细胞外囊泡包载卡介苗裂解物制备成新型载药囊泡，兼具直接杀伤肿瘤细胞和激活抗肿瘤免疫应答双重功能，同时具有较高的生物安全性。
Resumen de: AU2023385485A1
The present disclosure provides inhibitory nucleic acids, compositions comprising the inhibitory nucleic acids, and methods of using the inhibitory nucleic acids to treat various disorders.
Resumen de: MX2025002504A
Compositions and methods for making and using engineered NK cells, T cells and B cells that express a chimeric antigen receptor.
Resumen de: WO2024052698A1
The present invention relates to compositions, in particular to lipid-based compositions that solubilise and/or encapsulate (sometimes high concentrations of) copper complex(es) (and/or derivatives or analogues thereof). Such lipid-based compositions offer a variety of uses, including in their capacity as topical or ingestible formulations. Such compositions permit delivery of high concentrations of copper complex(es) (and derivatives) in a highly bioavailable form.
Resumen de: WO2024125469A1
Disclosed herein are novel compounds and compositions involving the same, lipid particles including the novel compounds, as well as additional lipids such as phospholipids, structural lipids, and PEG lipids, and the use of the compounds or the lipid particles in the delivery of a therapeutic agent to a subject, targeted organs, or targeted cells.
Resumen de: WO2024102434A1
Disclosed herein are RNA compositions including one or more polynucleotides encoding one or more gene editing systems, formulated within a lipid reconstructed natural messenger pack (LNMP) comprising natural lipids and an ionizable lipid. The disclosure also includes a method for making an RNA composition, comprising reconstituting a film comprising purified NMP lipids in the presence of an ionizable lipid to produce a LNMP comprising the ionizable lipid, and loading into the LNMPs with one or more polynucleotides encoding one or more gene editing systems. The disclosure also includes an RNA composition that is repeat dosable.
Resumen de: AU2023307461A1
The present invention relates to a high-Z element containing nanoparticles for use in a method of treating a tumor by radiopharmaceutical therapy, in a subject in need thereof, the method comprising a combined administration of an efficient amount of said high-Z element containing nanoparticles and of an efficient amount of a radionuclide containing therapeutic radiopharmaceutical, wherein the high-Z element containing nanoparticles contain an element with an atomic Z number higher than 40, preferably higher than 50, and wherein said nanoparticles have a mean hydrodynamic diameter of 20 nm or less, for example between 1 and 10 nm, preferably between 2 and 8 nm.
Resumen de: US2025120914A1
The present disclosure relates to lipid nanoparticles and methods of delivering active agents to target organs, tissues, or cells by utilizing the lipid nanoparticles.
Resumen de: TW202432138A
The present invention relates to a novel ionizable lipid compound represented by formula (I) or a salt thereof, and lipid nanoparticles including the same. Lipid nanoparticles including a novel ionizable lipid compound according to the present invention have excellent nucleic acid encapsulation efficiency and high cell delivery efficiency of nucleic acids.
Resumen de: CN120346182A
本发明属于生物医药技术领域，具体涉及一种新型锰基纳米颗粒及制备方法和在抗癌中的应用。本发明首先提供了一种新型锰基纳米颗粒，所述新型锰基纳米颗粒由带正电荷的内核和带负电荷的外壳通过静电吸附作用形成，所述内核为高锰酸钾和聚醚酰亚胺发生氧化还原反应得到，为氧化锰‑聚醚酰亚胺复合体；所述外壳为阴离子聚合物。本发明还进一步提供了所述新型锰基纳米颗粒的制备方法和载药用途。
Resumen de: CN120346311A
本发明公开了一种草鱼呼肠孤病毒Ⅱ型mRNA疫苗、其制备方法及应用，属于疫苗领域。其技术方案包括一种草鱼呼肠孤病毒Ⅱ型mRNA疫苗，包括：修饰后的mRNA链；修饰后的mRNA链序列包括：5’UTR序列、Kozak序列、草鱼免疫球蛋白μ重链信号肽编码序列、GCRV II外衣壳蛋白VP35编码序列、3个终止密码子、3’UTR序列和polyA核酸序列。本发明应用于增强鱼体抗GCRV病毒感染能力、降低死亡率，填补目前草鱼呼肠孤病毒Ⅱ型mRNA疫苗的空白。
Resumen de: CN120346184A
本发明涉及药物学技术领域，尤其涉及一种脂质纳米粒子及其制备方法和应用。所述脂质纳米粒子包括：纳米磷脂盘和IMB‑AL0912；所述纳米磷脂盘包括：肺黏液成分磷脂、负电磷脂、蛋黄卵磷脂和4F肽；以质量比计，4F肽和肺黏液成分磷脂的质量比为1：（5~10）。本发明针对多黏菌素类抗生素研究得到一种新的脂质纳米粒子，通过改进的纳米磷脂盘负载多黏菌素类抗生素IMB‑AL0912得到的脂质纳米粒子，具备显著降低LPS刺激造成的细胞损伤、炎症因子表达的效果，对于细菌感染和败血症有着显著较优的防治效果，同时毒性更低，具有更广的临床应用范围。
Resumen de: CN120349507A
本发明提供一种聚氨基酸高分子材料，其化学式如下式所示：#imgabs0#，R1为亲水氨基酸重复片段或亲水与疏水氨基酸重复片段的组合；R2为连接子，用于连接亲水基团和疏水基团；R3为过渡子，用于加固疏水基团的连接，防止取代反应的发生；式中的六元环选自苯环、环己烷、杂环己烷、环己烯、杂环己烯、吡啶或吡喃中的至少一种；n和m为自然数。本发明使用聚氨基酸高分子材料代替PEG脂质，可有效规避预存抗PEG抗体的影响，拥有良好的生物可降解性，有效提高纳米粒的物理分散稳定性，增加纳米粒在体内的长循环，可将传统脂质纳米粒的四组份减少为三组份配方，使所制备的脂质体及纳米晶制剂在一定时间内具有优秀稳定性，保留脂质体本身的载药优势。
Resumen de: CN117919199A
The invention provides application of blank lipid nanoparticles in preparation of in-vivo delivery products, and belongs to the technical field of biological medicines. The application of the blank lipid nanoparticles in preparation of the in-vivo delivery product comprises the step of mixing the blank lipid nanoparticles with a biological active substance in a solvent to obtain a composition based on the blank lipid nanoparticles, the blank lipid nanoparticles comprise ionizable lipid, phospholipid, cholesterol and polyethylene glycol conjugated lipid. The blank lipid nanoparticles are adopted, the dosage of biological active substances can be flexibly adjusted according to the requirements of a user, drug delivery can be conducted in various ways such as intravenous injection, intramuscular injection, intraperitoneal injection and subcutaneous injection, and the ideal delivery effect can be obtained.
Nº publicación: ES3032558A1 21/07/2025
Solicitante:
SERVICIO ANDALUZ DE SALUD [ES]
UNIV MALAGA [ES]
UNIV SEVILLA [ES]
CONSORCIO CENTRO DE INVESTIG BIOMEDICA EN RED [ES]
SERVICIO ANDALUZ DE SALUD,
Universidad de M\u00E1laga,
Universidad de Sevilla,
Consorcio Centro de Investigaci\u00F3n Biom\u00E9dica en Red
BOPI
Sede Electrónica
